Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events

Autoimmunity Reviews

Volumn 11, Issue 1, 2011, Pages 56-60

  Murdaca, Giuseppe ^a   Colombo, Barbara Maria ^a   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

B cells; Biological therapies; Cytokines; Systemic Lupus Erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; ADALIMUMAB; AMG 108; AZATHIOPRINE; BELIMUMAB; CERTOLIZUMAB PEGOL; COMPLEMENT INHIBITOR; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ECULIZUMAB; EFALIZUMAB; EPRATUZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10 ANTIBODY; LJP 1082; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TP 10; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LATENT TUBERCULOSIS; LOW DRUG DOSE; LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SERUM SICKNESS; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80855130786     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.07.006     Document Type: Review

References (64)

1. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
2. Meroni P.L., Shoenfeld Y. Systemic lupus erythematosus and the SLE galaxy. Autoimmun Rev 2010, 10:1-2.
3. Leng R.X., Pan H.F., Chen G.M., Feng C.C., Fan Y.G., Ye D.Q., et al. The dual nature of Ets-1: focus to the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2011, 10:439-443.
4. Crispín J.C., Liossis S.N.C., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57.
5. Campar A., Farinha F., Vasconcelos C. Refractory disease in Systemic Lupus Erythematosus. Autoimmun Rev May 11 2011, 10.1016/j.autrev.2011.04.027.
6. Arnaud L., Zahr N., Costedoat-Chalumeau N., Amoura Z. The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmun Rev May 10 2011, 10.1016/j.autrev.2011.04.029.
7. Looney R.J., Anolik J., Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004, 16:180-185.
8. Anolik J.H., Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005, 19:859-878.
9. Mount G.R., Gilliland W.R. Emerging biological therapies in systemic lupus erythematosus. Clin Pharmacol Ther 2008, 83:167-171.
10. Picchianti Diamanti A., Rosado M.M., Carsetti R., Valesini G. B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev 2007, 7:143-148.
11. Guzman Moreno R. B-cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimmun Rev 2009, 8:585-590.
12. Dong W., Zhu P., Wang Y., Wang Z. Follicular helper T cells in systemic lupus erythematosus: a potential therapeutic target. Autoimmun Rev 2011, 10:299-304.
13. Perosa F., Favoino E., Caragnano M.A., Prete M., Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005, 4:526-531.
14. Wang C., Pan H.F., Ye D.Q. The therapeutic potential of the targeted autoreactive B lymphocytes by rituximab in SLE. Autoimmun Rev Jan 9 2011, 10.1016/j.autrev.2011.01.002.
15. Gunnarson I., Sundelin B., Jonsdottir T., Jacobson S.H., Henriksonn E.W., van Vollenhoven R.F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007, 56:1263-1272.
16. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
17. García-Carrasco M., Jiménez-Hernández M., Escárcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009, 8:343-348.
18. Galarza-Maldonado C., Kourilovitch M.R., Molineros J.E., Cardiel M.H., Zurita L., Soroka N.F., et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Autoimmun Rev 2010, 10:108-111.
19. Furie R., Looney R.J., Rovin B., Latinis B., Kevin M., Appel G., et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 2009, 60(Suppl. 1):S429.
20. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab inmoderately-to-severely active systemic lupus erythematosus: the randomized double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
21. Sanz I., Lee F.E. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337.
22. Turner-Stokes T., Lu T.Y., Ehrenstein M.R., Giles I., Rahman A., Isenberg D.A. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology March 12 2011, 10.1093/rheumatology/ker018.
23. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Baldovino S., et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant March 9 2011, 10.1093/ndt/gfr109.
24. Rituxan warning. FDA Consum 2007, 41:3.
25. Sato S., Miller A.S., Inaoki M., Bock C.B., Jansen P.J., Tang M.L., et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996, 5:551-562.
26. O'Keefe T.L., Williams G.T., Batista F.D., Neuberger M.S. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999, 189:1307-1313.
27. Jacobi A.M., Goldenberg D.M., Hiepe F.T., Radbruch A., Burmester G.R., Dorner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008, 67:450-457.
28. Wallace D.J., Hobbs K., Houssiau F., Strand V., Tak P., Wegener W., et al. Randomized controlled trials of epratuzumab (anti-CD-22MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid use with favorable safety profile in moderate and severe flaring SLE patients. Ann Rheum Dis 2008, 67(Suppl. II):212.
29. Petri M.A., Hobbs K., Gordon C., Strand V., Wallace D., Kelley L., et al. Randomized controlled trials of epratuzumab (anti-CD-22MAB targeting B cells) reveal clinically meaningful improvements in patients with moderate and severe SLE flares. Ann Rheum Dis 2008, 67(Suppl. II):53.
30. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48:3475-3486.
31. Furie R. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BlyS) in SLE patients [abstract]. Arthritis Rheum 2003, 48(Suppl):S377.
32. Furie R., Stohl W., Ginzler E.M., Becker M., Mishra N., Chatham W., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R109.
33. Navarra S.V., Guzmán R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
34. Manzi S., Sanchez-Guerrero J., Merrill J.T., Furie R.A., Gladman D., Navarra S., et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studies [abstract]. Arthritis Rheum 2010, 62:S607. Suppl.
35. Strand V., Crawford B. Improved health-related quality of life [HRQOL] following sustained reduction in anti-dsDNA antibody levels in patients with systemic lupus erythematosus [SLE] after treatment with LJP 394. Arthritis Rheum 2004, 50:S198.
36. Cockerill K.A., Iverson G.M., Jones D.S., Linnik M.D. Therapeutic potential of toleragens in the management of antiphospholipid syndrome. BioDrugs 2004, 18:297-305.
37. Grammer A.C., Lipsky P.E. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002, 46:1417-1429.
38. Wang X., Huang W., Schiffer L.E., Mihara M., Akkerman A., Hiromatsu K., et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003, 48:495-506.
39. Kalunian K.C., Davis J.C., Merrill J.T., Totoritis M.C., Wofsy D. IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258.
40. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
41. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807-2816.
42. Finck B.K., Linsley P.S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
43. Daikh D.I., Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 166:2913-2916.
44. Usmani N., Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007, 143:873-877.
45. Bao L., Quigg R.J. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol 2007, 27:69-80.
46. Grondal G., Kristjansdottir H., Gunnlaugsdottir B., Arnason A., Lundberg I., Klareskog L., et al. Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 1999, 42:1649-1654.
47. van der Linden M.W., Westendorp R.G., Sturk A., Bergman W., Huizinga T.W., et al. High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J Investig Med 2000, 48:327-334.
48. Ronnelid J., Tejde A., Mathsson L., Nilsson-Ekdahl K., Nilsson B., et al. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003, 62:37-42.
49. Sun K.H., Yu C.L., Tang S.J., Sun G.H., et al. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000, 99:352-360.
50. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1790-1800.
51. Illei G.G., Shirota Y., Yarboro C.H., Daruwalla J., Tackey E., Takada K., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552.
52. Takemura T., Yoshioka K., Murakami K., Akano N., Okada M., Aya N., et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 1994, 424:459-464.
53. Ostendorf B., Iking-Konert C., Kurz K., Jung G., Sander O., Schneider M., et al. Preliminary results of safety and efficacy of the interleukin-1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005, 64:630-633.
54. Nash P.T., Florin T.H. Tumour necrosis factor inhibitors. Med J Aust 2005, 183:205-208.
55. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
56. Hochberg M.C., Lebwohl M.G., Plevy S.E., Hobbs K.F., Yocum D.E. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005, 34:819-836.
57. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011, 10:563-568.
58. Bender N.K., Heilig C.E., Dröll B., Wohlgemuth J., Armbruster F.P., Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007, 27:269-274.
59. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., Di Franco M. Biological and clinical effects of anti-TNFα treatment. Autoimmun Rev 2007, 7:35-41.
60. Aringer M., Graninger W.B., Steiner G., Smolen J.S. Safety and efficacy of TNFα blockade in systemic lupus erythematosus-an open label study. Arthritis Rheum 2004, 50:3161-3169.
61. Ramos-Casals M., Perez-Alvarez R., Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents A double-edged sword?. Autoimmun Rev 2010, 9:188-193. BIOGEAS Study Group.
62. Soforo E., Baumgartner M., Francis L., et al. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2011, 37:204-205.
63. Aringer M., Smolen J.S. Therapeutic blockade of TNF in patients with SLE-promising or crazy?. Autoimmun Rev May 18 2011, 10.1016/j.autrev.2011.05.001.
64. Pittoni V., Bombardieri M., Spinelli F.R., Scrivo R., Alessandri C., Conti F., et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002, 61:723-725.